Literature DB >> 26115903

Factors predicting severe infections during chemotherapy in head and neck cancer patients.

Takahiro Sasaki1, Yukinori Takenaka, Tarou Hayashi, Masashi Yamamoto, Hironori Cho, Takahito Fukusumi, Norihiko Takemoto, Atsushi Hanamoto, Toshimichi Yasui, Susumu Nakahara, Yoshifumi Yamamoto, Kenji Mitani, Hidenori Inohara.   

Abstract

CONCLUSIONS: The head and neck cancer patients with more co-morbidities and those dependent on tube feeding are at a high risk of severe infections during chemotherapy. Therefore, prophylaxis with colony-stimulating factors and/or antibiotics should be considered for those patients.
OBJECTIVES: To investigate the risk factors for severe infection during chemotherapy in head and neck cancer patients.
METHODS: A retrospective study was conducted of 129 patients with head and neck cancer who received taxane-based and platinum-based chemotherapy between 2008-2013. Logistic regression models were used to evaluate risk factors.
RESULTS: Febrile neutropenia occurred in 50 patients out of the 129 (39%), severe infections occurred in 24 patients (19%), and bacteremia in two patients (2%). In univariate analysis, low serum albumin levels and tube feeding were significantly associated with severe infections (p = 0.015 and < 0.001, respectively). In multivariate analysis, the odds ratios for a higher modified Charlson co-morbidity index and tube feeding were 2.80 and 9.74, respectively. These two were independent predictive factors for severe infections (p = 0.020 and 0.001, respectively).

Entities:  

Keywords:  Chemotherapy; co-morbidity; febrile neutropenia; sepsis; septic shock; severe sepsis; tube feeding

Mesh:

Substances:

Year:  2015        PMID: 26115903     DOI: 10.3109/00016489.2015.1060631

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).

Authors:  Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild
Journal:  Ann Hematol       Date:  2021-04-13       Impact factor: 3.673

2.  Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.

Authors:  Marie Shimanuki; Yorihisa Imanishi; Yoichiro Sato; Nana Nakahara; Daisuke Totsuka; Emiri Sato; Sena Iguchi; Yasuo Sato; Keiko Soma; Yasutomo Araki; Seiji Shigetomi; Satoko Yoshida; Kosuke Uno; Yusuke Ogawa; Takehiro Tominaga; Yuichi Ikari; Junko Nagayama; Ayako Endo; Koshiro Miura; Takuya Tomioka; Hiroyuki Ozawa; Kaoru Ogawa
Journal:  Oncotarget       Date:  2018-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.